Novo Nordisk trying to stop exports of Russian generic of Ozempic
The Danish company Novo Nordisk (NOV: N) is trying to stop exports of the Russian generic of Ozempic (semaglutide), which has been produced by the Russian Geropharm for two years, reports The Pharma Letter’s local correspondent.
The Russian semaglutide-based generic replaced the original Ozempic, which left the Russian market. According to Russian analytical company DSM Group, pharmacy sales of semaglutide-based drugs almost tripled in the first nine months of 2025 compared to 2024, reaching 13 billion roubles ($165 million). Novo Nordisk accounted for only 3% of total sales last year.
This year, Geropharm launched its generic version in three foreign markets: Kazakhstan, Azerbaijan, and Paraguay. According to Russian analysts, currently the Danish company has serious fears of losing customers in some key foreign markets for itself.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze